{"id":"alogliptin-pioglitazone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":{"setId":"642b1e90-701e-42f2-bac6-a4918738e2c9","title":"ALOGLIPTIN AND PIOGLITAZONE (ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE) TABLET, FILM COATED [PADAGIS ISRAEL PHARMACEUTICALS LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets type 2 diabetes through two complementary pathways. Alogliptin prevents the breakdown of incretin hormones, enhancing glucose-dependent insulin secretion and reducing glucagon. Pioglitazone acts as an insulin sensitizer by activating PPAR-γ in adipose tissue and muscle, reducing hepatic glucose production and improving peripheral glucose uptake.","oneSentence":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:21:07.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT01990300","phase":"","title":"Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11-28","conditions":"Type 2 Diabetes Mellitus","enrollment":3281},{"nctId":"NCT01686711","phase":"PHASE4","title":"A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-09","conditions":"Diabetes Mellitus","enrollment":207},{"nctId":"NCT04980014","phase":"","title":"A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":730},{"nctId":"NCT04470310","phase":"PHASE4","title":"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-12-31","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT03950505","phase":"PHASE4","title":"To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-29","conditions":"Non-alcoholic Steatohepatitis, Type2 Diabetes","enrollment":60},{"nctId":"NCT04392557","phase":"PHASE4","title":"Anti-inflammatory Status in DM2 Treated Patients","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03501277","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-05-26","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT02763007","phase":"PHASE4","title":"An Extension Study of PEAK Trial","status":"TERMINATED","sponsor":"Kun-Ho Yoon","startDate":"2016-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT02823808","phase":"PHASE4","title":"Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2017-07","conditions":"Diabetes","enrollment":96},{"nctId":"NCT02683226","phase":"PHASE4","title":"Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2015-03","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":30},{"nctId":"NCT02426294","phase":"PHASE4","title":"Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT00655863","phase":"PHASE3","title":"Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Diabetes Mellitus","enrollment":71},{"nctId":"NCT00328627","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1554},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT00395512","phase":"PHASE3","title":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-11","conditions":"Diabetes Mellitus","enrollment":655},{"nctId":"NCT01289119","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01318122","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":336},{"nctId":"NCT00286494","phase":"PHASE3","title":"Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":493},{"nctId":"NCT01318070","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus","enrollment":339}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nesina","Actos"],"phase":"marketed","status":"active","brandName":"alogliptin + pioglitazone","genericName":"alogliptin + pioglitazone","companyName":"Kun-Ho Yoon","companyId":"kun-ho-yoon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}